Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-intrinsic activation of the Wnt/β-catenin pathway (15) and deletion or mutation of Pten (16) have been shown to lead to deficient T cell infiltration into the tumor microenvironment and resistance to checkpoint blockade immunotherapy.”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [15]
In the citing paper
“We reveal that the APOE variants exert cell-intrinsic effects on melanoma that impact primary tumor growth and metastatic capacity in a BrafV600E-driven GEMM, a model that has provided numerous important insights into melanoma biology (12,38–40).”
From Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis (2023) · cites this paper as [12]
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“For example, tumor cell-intrinsic WNT/β-catenin activation has been shown to lead to exclusion of T cells within the TME (123, 155, 156).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“Mechanistic studies revealed that Wnt-induced decrease in the expression of the chemokine CCL4 hindered the recruitment of CD103+ DCs and T cells to the tumor microenvironment (Spranger et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Spranger et al., 2015
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 701–800 of 1,015
Wnts and the hallmarks of cancer
Zhong, Z., Yu, J., Virshup, D. M., & Madan, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09887-6 · Cited by 85
“In these tumors, β-catenin activation reduced CCL4 chemokine expression that was required for the recruitment of the DCs via repression of ATF3-dependent transcription [168].”
BackgroundZhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 90
“first reported that the tumorintrinsic Wnt/b-catenin activation is the main cause of immune desert (91).”
BackgroundYu, K.-X., Yuan, W.-J., Wang, H.-Z., & Li, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03675-9 · Cited by 95
“…result in melanoma tissue samples also confirmed that the high expression of β-catenin was mainly found in tumors lacking CD8 + T cells, indicating that there was a significant negative correlation between the activation of β-catenin pathway and a T cell-inflamed tumor microenvironment [44].”
BackgroundCappuyns, S., Piqué‐Gili, M., Esteban-Fabró, R., Philips, G., Balaseviciute, U., Pinyol, R., Gris‐Oliver, A., Vandecaveye, V., Abril‐Fornaguera, J., Montironi, C., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.016 · Cited by 106
Antigen Presentation in Transplantation
Alegre, M., Lakkis, F. G., & Morelli, A. E. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.003 · Cited by 83
Bao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 88
Self-citationTranscriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Cristescu, R., Nebozhyn, M., Zhang, C., Albright, A. V., Kobie, J., Huang, L., Zhao, Q., Wang, A., Ma, H., Cao, Z. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3329 · Cited by 82
“, proliferation (8), immunosuppression by WNT inhibition (9), hypoxia (10), glycolysis (11), and angiogenesis] may be relevant to cancer progression and response to ICI therapy.”
BackgroundOdunsi, K. O., Qian, F., Lugade, A. A., Yu, H., Geller, M. A., Fling, S. P., Kaiser, J. C., Lacroix, A. M., D’Amico, L., Ramchurren, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8402 · Cited by 83
Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13805 · Cited by 80
Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
Haas, L., & Obenauf, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02746 · Cited by 88
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Dai, X., Guo, Y., Hu, Y., Bao, X., Zhu, X., Fu, Q., Zhang, H., Tong, Z., Liu, L., Zheng, Y., et al. (2021) · Theranostics · doi:10.7150/thno.54648 · Cited by 88
“Intriguing studies have demonstrated that the aberrant activation of the tumor-intrinsic Wnt/β-Catenin signaling pathway correlates with a low proportion of T cell infiltration in the tumor microenvironment (TME) of HCC and melanoma tumor samples [33, 34].”
BackgroundGarris, C., Wong, J. L., Ravetch, J. V., & Knorr, D. A. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1346 · Cited by 81
“DCs, in particular cDC1s, have been found to be strongly associated with cancer immune surveillance and immunotherapy response (27, 45, 46, 47), and cDC1 exclusion from the TME can act as an immune evasion strategy prohibiting development of antitumor T cell responses (48, 49).”
BackgroundWu, C.-C., Wang, Y., Livingston, J. A., Zhang, J., & Futreal, P. A. (2022) · Nature Communications · doi:10.1038/s41467-021-27651-4 · Cited by 86
Wang, Y., Chen, J., Chang, C.-W., Jen, J., Huang, T.-Y., Chen, C., Shen, R., Liang, S., Cheng, I., Yang, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89957 · Cited by 87
“On one hand, activation of tumor-intrinsic oncogenes such as β -caten- in ( CTNNB1 ) (51), STAT3 (52, 53), enhancer of zeste 2 polycomb– repressive complex 2 subunit ( EZH2 ), and DNA methyltransferase 1 ( DNMT1 ) (54) and loss of function of the tumor suppressor p53 (55) have been shown to…”
Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype
Sinnberg, T. W., Levesque, M. P., Krochmann, J., Cheng, P. F., Ikenberg, K., Meraz-Torres, F., Niessner, H., Garbe, C., & Busch, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0773-5 · Cited by 85
“A second plausible explanation for resistance to the novel immunotherapies might be the tumor-intrinsic oncogenic signals such as active β-catenin signaling, that mediate T-cell exclusion at the site of the tumor and thus resistance to anti-PD-L1/antiCTLA-4 therapy [38, 60].”
BackgroundPredictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli, F., & Fumet, J.-D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01816 · Cited by 84
“In particular, CCL4 expression induces recruitment of Batf3 positive dendritic cells which are essential for T cell priming, activation and recruitment to the tumor site (25, 26).”
BackgroundLung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity
Li, L., Yang, L., Cheng, S., Fan, Z., Shen, Z., Xue, W., Zheng, Y., Li, F., Wang, D., Zhang, K., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1027-x · Cited by 76
“It has been shown that tumor-intrinsic active β-catenin signaling results in decreased CCL4 production, which further induces T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy [63].”
BackgroundFriedman, C. F., Snyder, A., Zhou, Q. C., Carducci, M. A., de Meritens, A. B., Corr, B. R., Fu, S., Hollmann, T. J., Iasonos, A. E., Konner, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001126 · Cited by 85
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 83
“In addition, the blockade of CTLA-4 increases effector Tcell-to-Treg ratios in the TME [121], inducing a shift in the intratumoral balance from an immunosuppressive to a permissive state.”
BackgroundInfluentialUncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle
Cheng, W.-C., Tsui, Y., Ragusa, S., Koelzer, V. H., Mina, M., Franco, F., Laubli, H. P., Tschumi, B., Speiser, D. E., Romero, P. J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0290-0 · Cited by 85
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 89
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 81
Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
Gu, Y., Zhang, Z., & ten Dijke, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00980-8 · Cited by 79
“Aberrant oncogenic/tumor suppressor signals A series of studies across different types of cancer have indicated that augmented WNT/β-catenin signaling [154, 155], increases mitogen-activated protein kinase (MAPK) signaling [156] and that Fig.”
BackgroundComputational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 85
Immune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M., Matthew Barnes, J., Tanlimco, S. G., Lu, R., Halliwill, K., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 75
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 74
Principe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M. W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584423 · Cited by 93
Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma
Nowicki, T. S., Akiyama, R., Huang, R. R., Shintaku, I. P., Wang, X., Tumeh, P. C., Singh, A., Chmielowski, B., Denny, C., Federman, N., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0148 · Cited by 73
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 80
“WNT/β-catenin signaling upregulation may be one of the tumor cell-intrinsic pathways driving a non-T-cell inflamed phenotype, at least in metastatic melanoma (29) for which a genetically engineered mouse model revealed reduced expression of the chemokine CCL4, impaired recruitment of Batf3+ DCs and T-cells, and resist…”
BackgroundGuillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
Dijkstra, K. K., Voabil, P., Schumacher, T. N., & Voest, E. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2214 · Cited by 75
Chae, Y. K., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Agte, S., Giles, F. J., & Chuang, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39594-4 · Cited by 79
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
Kato, S., Weng, Q. Y., Insco, M. L., Chen, K. Y., Muralidhar, S., Poźniak, J., Diaz, J. M. S., Drier, Y., Nguyen, N. T., Lo, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0532 · Cited by 79
“, poor recruitment of CD8+ T-cells) and resistance to immune checkpoint (30).”
BackgroundInactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
Gstalder, C., Liu, D., Miao, D., Lutterbach, B. A., DeVine, A. L., Lin, C., Shettigar, M., Pancholi, P., Buchbinder, E. I., Carter, S. L., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1416 · Cited by 78
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Kozani, P. S., Kozani, P. S., Najafabadi, M. A., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795164 · Cited by 77
Aguilera, T. A., & Giaccia, A. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0189 · Cited by 78
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
Chiaruttini, G., Mele, S., Opzoomer, J. W., Crescioli, S., Ilieva, K. M., Lacy, K. E., & Karagiannis, S. N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1294296 · Cited by 76
Wang, D., Yu, W., Lian, J., Wu, Q., Liu, S., Yang, L., Li, F., Huang, L. J., Chen, X., Zhang, Z., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00897-z · Cited by 80
Cadoux, M., Caruso, S., Pham, S., Gougèlet, A., Pophillat, C., Riou, R., Loesch, R., Colnot, S., Nguyễn, C. T., Caldéraro, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.017 · Cited by 81
Learning from PD-1 Resistance: New Combination Strategies
Bu, X., Mahoney, K. M., & Freeman, G. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.008 · Cited by 71
“As illustrated in Figure 1, the IPRES signature includes genes involved in immunosuppression (IL10) and angiogenesis (VEGFA, VEGFC, FLT1, and ANGPT2), monocyte and macrophage chemotaxis (CCL2, CCL7, CCL8, CCL13) and epithelial-mesenchymal transition (EMT) (AXL, ROR2, WNT5A, LOXL2, TWIST2, TAGLN, FAP).”
BackgroundInfluentialNeoantigens encoded in the cancer genome
Schumacher, T. N., & Hacohen, N. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.005 · Cited by 80
“Finally, the specific oncogenic pathways activated within a tumor can influence T cell priming and attraction capacity, thereby creating a barrier against immune control of intrinsically foreign tumors [19,20].”
BackgroundA Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Weber, J. S., Sznol, M., Sullivan, R. J., Blackmon, S. M., Boland, G. M., Kluger, H. M., Halaban, R., Bacchiocchi, A., Ascierto, P. A., Capone, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0412 · Cited by 76
Immunomodulation of Tumor Vessels: It Takes Two to Tango
Johansson-Percival, A., He, B., & Ganss, R. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.08.001 · Cited by 73
Intergroup, O. B. O. T. I. M., Massi, D., Rulli, E., Cossa, M., Valeri, B., Rodolfo, M., Merelli, B., Logu, F. D., Nassini, R., Vecchio, M. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0797-4 · Cited by 77
“dendritic cells tumor infiltrate via inhibition of CCL4 secretion [11], have been reported to promote acquired resistance to BRAFi and MEKi [12].”
BackgroundThe Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier
Pai, S. I., Cesano, A., & Marincola, F. M. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_6 · Cited by 81
Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
Bujanda, Z. A. L., & Drake, C. G. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-491rr · Cited by 78
WNT and β-Catenin in Cancer: Genes and Therapy
Jackstadt, R., Hodder, M. C., & Sansom, O. J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033628 · Cited by 64
“S ee c op yr ig ht f or a pp ro ve d us e. (Stadeli et al. 2006).”
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaïb, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 80
“First, Thomas Gajewski and co-workers, using human melanoma samples and mouse melanoma models, demonstrated that activation of tumor cell WNT signaling resulted in absence of CD8 T cells, mediated via down-regulated expression of a chemokine and down-regulated influx of dendritic cells [118].”
BackgroundStein, J. E., Soni, A., Danilova, L., Cottrell, T. R., Gajewski, T. F., Hodi, F. S., Bhatia, S., Urba, W. J., Sharfman, W. H., Wind-Rotolo, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz019 · Cited by 73
Self-citationImmune profiles in primary squamous cell carcinoma of the head and neck
Saloura, V., Izumchenko, E., Zuo, Z., Bao, R., Korzinkin, M., Ozerov, I. V., Zhavoronkov, A. A., Sidransky, D., Bedi, A., Hoque, M. O., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.032 · Cited by 74
Self-citationBiomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Boshuizen, J., Pencheva, N., Krijgsman, O., Altimari, D. M. D., Castro, P. G., de Bruijn, B., Ligtenberg, M. A., den Heuvel, E. G.-V., Vredevoogd, D. W., Song, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0434 · Cited by 74
Jiang, T., Chen, X., Ren, X., Yang, J., & Cheng, Y. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100752 · Cited by 73
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Leary, A. F., Tan, D. S. P., & Ledermann, J. A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211039899 · Cited by 87
Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues
Şahin, İ. H., Ciombor, K. K., Diaz, L. A., Yu, J. B., & Kim, R. D. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349811 · Cited by 86
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Kim, H., Jung, S., Lim, H. Y., Ryoo, B., Ryu, M., Chuah, S., Chon, H. J., Kang, B., Hong, J. Y., Lee, H. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02824-y · Cited by 80
Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01523-4 · Cited by 81
“Activated Wnt/β-catenin pathway also contributes to immune evasion and resistance to immunotherapies in GC 16, and inhibitors of the Wnt/β-catenin pathway could be promising combination partners for ICIs [272].”
BackgroundLi, X., Sun, Y.-Y., Bao, J., Chen, X., Li, Y., Yang, Y., Zhang, L., Huang, C., Wu, B., Meng, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12570-6 · Cited by 73
Jia, D., Li, X., Bocci, F., Tripathi, S., Deng, Y., Jolly, M. K., Onuchic, J. N., & Levine, H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050725 · Cited by 84
“The inconsistency can be simply due to the fact that different analyses use varying standards of assessing the abundance of cancer-killing immune cells, for example, gene expression signatures of cancer-killing immune cells [189] or the percentage of cancer-killing immune cells among all (immune) cells [173].”
InfluentialTherapeutic Targeting of the Colorectal Tumor Stroma
Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 79
Extracellular vesicles and oncogenic signaling
Schubert, A., & Boutros, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12855 · Cited by 77
Control of Dendritic Cell Function Within the Tumour Microenvironment
Hari‐Gupta, Y., Khanom, A., & Acton, S. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.733800 · Cited by 78
Badal, B., Solovyov, A., Cecilia, S. D., Chan, J. M., Chang, L., Iqbal, R., Aydin, I. T., Rajan, G. S., Chen, C., Abbate, F., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92102 · Cited by 77
““Immune” subtypes, previously described by others, were evident in our cohort, verifying previous observations (18, 35), and served as biological controls.”
MethodResultPavlovic, Z., Adams, J., Blazer, L. L., Gakhal, A. K., Jarvik, N., Steinhart, Z., Robitaille, M., Mascall, K. S., Pan, J., Angers, S., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1515565 · Cited by 73
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy
Zhu, S., Yang, N., Wu, J., Wang, X., Wang, W., Liu, Y.-J., & Chen, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104980 · Cited by 71
Acha-Sagredo, A., Andrei, P., Clayton, K., Taggart, E., Antoniotti, C., Woodman, C. A., Afrache, H., Fourny, C., Armero, M., Moinudeen, H. K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.12.008 · Cited by 71
Yamada, K., Hori, Y., Inoue, S., Yamamoto, Y., Iso, K., Kamiyama, H., Yamaguchi, A., Kimura, T., Uesugi, M., Ito, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0782 · Cited by 76
“Wnt/b-catenin signal– activated murine melanoma shows impaired priming of antitumor T cells and suppression of the recruitment of CD103þDCs because of decreased expression of CCL4 (14).”
BackgroundBallesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 83
Renal Cell Cancer – Insights in Drug Resistance Mechanisms
AWEYS, H., LEWIS, D., Sheriff, M., Rabbani, R. D., Lapitan, P., Sanchez, E., Papadopoulos, V. P., Ghose, A., & Boussios, S. (2023) · Anticancer Research · doi:10.21873/anticanres.16675 · Cited by 78
“Mutations that elevate β-catenin levels contribute to the depletion of CD103+ dendritic cells (61).”
BackgroundHuang, J. C., Theelen, W. S. M. E., Belcaid, Z., Najjar, M., van der Geest, D., Singh, D., Cherry, C., Balan, A., White, J. R., Wehr, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01018-w · Cited by 87
“Notably, we found a numerically higher frequency of mutations in genes in the canonical Wnt–β-catenin pathway in responding tumors in the SBRT arm, which was particularly interesting given the expected T cell exclusion of such tumors 20 (Fig.”
Zito Marino, F., Ascierto, P. A., Rossi, G., Staibano, S., Montella, M., Russo, D., Alfano, R., Morabito, A., Botti, G., & Franco, R. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309387 · Cited by 73
Takahashi, H., Kawaguchi, T., Yan, L., Peng, X., Qi, Q., Morris, L. G. T., Chan, T. A.-T., Tsung, A., Otsuji, E., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12051221 · Cited by 76
“Beta-catenin pathway activation or an increased CTNNB1 score resulted in T cell exclusion and demonstrated resistance to ICIs in melanomas and hepatocellular carcinomas (HCCs) [7,11].”
BackgroundImmunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 73
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 76
Recent advances in understanding antitumor immunity
Munhoz, R. R., & Postow, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9356.1 · Cited by 82
The effects of age and systemic metabolism on anti-tumor T cell responses
Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69
“DOI: https://doi.org/10.7554/eLife.62420 12 of 29 (Spranger et al., 2015).”
InfluentialAcquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
O’Donnell, J. S., Smyth, M. J., & Teng, M. W. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0365-1 · Cited by 69
“priming [8], limited intra-tumoral T-cell infiltration, elevated PD1 expression on tumor-infiltrating T cells representing a state of severe functional exhaustion [1], and the”
Blons, H., Garinet, S., Laurent‐Puig, P., & Oudart, J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.48 · Cited by 76
The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
Cabrita, R., Mitra, S., Sanna, A., Ekedahl, H., Lövgren, K., Olsson, H. L., Ingvar, C., Isaksson, K., Lauss, M., Carneiro, A., et al. (2020) · Cancers · doi:10.3390/cancers12030742 · Cited by 75
Sun, Z., Deng, G., Peng, X., Xu, X., Liu, L., Peng, J., Ma, Y., Zhang, P., Wen, A., Wang, Y., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121228 · Cited by 70
Kovacs, D., Migliano, E., Muscardin, L., Silipo, V., Catricalà, C., Picardo, M., & Bellei, B. (2016) · Oncotarget · doi:10.18632/oncotarget.9232 · Cited by 77
Response to Anti–PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis
Johnson, D. B., Bao, R., Ancell, K. K., Daniels, A. B., Wallace, D. E., Sosman, J. A., & Luke, J. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7070 · Cited by 69
Self-citationZhang, Y., Jiang, X., Zhang, N., Chen, M., Wang, H., & Zhu, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.017 · Cited by 91
Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications
Prete, A. D., Sozio, F., Barbazza, I., Salvi, V., Tiberio, L., Laffranchi, M., Gismondi, A., Bosisio, D., Schioppa, T., & Sozzani, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113930 · Cited by 72
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
Hoefsmit, E. P., Rozeman, E. A., Van, T. M., Dimitriadis, P., Krijgsman, O., Conway, J. W., da Silva, I. P., van der Wal, J. E., Ketelaars, S. L. C., Bresser, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001501 · Cited by 73
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Haines, B. B., Denslow, A., Grzesik, P., Lee, J. S., Farkaly, T., Hewett, J., Wambua, D., Kong, L., Behera, P., Jacques, J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0609 · Cited by 73
Gordon, K. S., Kyung, T., Perez, C. R., Holec, P. V., Ramos, A., Zhang, A. Q., Agarwal, Y., Liu, Y., Koch, C. E., Starchenko, A., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00896-0 · Cited by 74
Muto, S., Enta, A., Maruya, Y., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010190 · Cited by 73
“Wnt/β-catenin can induce the expression of activating transcription factor 3 (ATF3), resulting in the reduction of CCL4 in a mouse model of melanoma [17].”
BackgroundMolecular mechanisms of immunotherapy resistance in triple-negative breast cancer
Zheng, Y., Li, S., Tang, H., Meng, X., & Zheng, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1153990 · Cited by 80
Epigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 73
The Role of Long Non-coding RNAs in Immunotherapy Resistance
Zhou, Y., Zhu, Y., Xie, Y., & Ma, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01292 · Cited by 70
Kato, S., Okamura, R., Kumaki, Y., Ikeda, S., Nikanjam, M., Eskander, R. N., Goodman, A. M., Lee, S., Glenn, S. T., Dressman, D. C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708065 · Cited by 70
A Review of the Role of Wnt in Cancer Immunomodulation
Goldsberry, W. N., Londoño, A. I., Randall, T. D., Norian, L. A., & Arend, R. C. (2019) · Cancers · doi:10.3390/cancers11060771 · Cited by 70
“Wnt pathway regulation may play a role in this lack of response, as tumor-intrinsic, active β-catenin signaling in human melanoma has been associated with resistance to anti-CTLA4 and anti-PD-L1 antibodies due to T cell exclusion [88].”
BackgroundInfluentialFujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
“There is an increasing body of evidence that the activation of different oncogenic cell signaling pathways can impair local anti-tumor immune response and are relevant across all the different stages of carcinogenesis([53,54]).”
BackgroundDeng, R., Zuo, C., Li, Y., Xue, B., Xun, Z., Guo, Y., Wang, X., Xu, Y., Tian, R., Chen, S., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00549-9 · Cited by 72
Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 74
The Tumor Microenvironment of Bladder Cancer
Hatogai, K., & Sweis, R. F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_17 · Cited by 81
Brown, K., Yang, P., Salvador, D., Kulikauskas, R. M., Ruohola‐Baker, H., Robitaille, A. M., Chien, A. J., Moon, R. T., & Sherwood, V. (2017) · Oncogene · doi:10.1038/onc.2016.450 · Cited by 69
Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
Bödder, J., Zahan, T., van Slooten, R., Schreibelt, G., de Vries, I. J. M., & Flórez‐Grau, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.631713 · Cited by 72
Metadata
- Authors
- Spranger, S., Bao, R., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Gajewski, Thomas F.
- Venue
- Nature
- Published
- 2015-05-11
- Volume
- 523
- Issue
- 7559
- Pages
- 231-235
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1498931318
- Cited by
- 2,830
- References
- 45
- Citations by year
- 2026: 240 · 2025: 234 · 2024: 222 · 2023: 270 · 2022: 319 · 2021: 367 · 2020: 337 · 2019: 246 · 2018: 198 · 2017: 212 · 2016: 151 · 2015: 31
- FWCI
- 86.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, β-catenin signaling, Wnt signaling, cancer immunotherapy resistance, PD-L1 blockade, CTLA-4 blockade, T-cell exclusion, tumor microenvironment, CD8+ T cell infiltration, tumor immune evasion, oncogenic signaling, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Signal Transduction, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Wnt Proteins, beta Catenin, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.